COVID-19 vaccine approved for trials, says Chinese military
The Chinese Ministry of National Defense (MND) announced on 18 March that a vaccine for the COVID-19 coronavirus, developed by the Academy of Military Medical Sciences of the People’s Liberation Army (PLA), has been approved for clinical trials.
The subunit vaccine has apparently been approved for safe testing on humans by an undisclosed (and therefore unverified) third party.
Preparations for mass production of the vaccine are also under way, the MND stated.
The team of PLA scientists worked under senior bioengineer Maj Gen Chen Wei. He has been conducting research in Wuhan, where the COVID-19 outbreak began.
A subunit vaccination includes a fragment of the pathogen that can initiate an immune response.
More from Defence Notes
-
Turning the Hiroshima Accord into Action: Enhancing UK-Japan Defence Collaboration (Studio)
The UK-Japan strategic partnership leverages joint defence initiatives, advanced technologies, and SME integration to enhance military capabilities, foster innovation, and ensure regional and global stability through collective action and effective project management.
-
NATO countries outline strategies to accelerate defence industrial production
During the Washington Summit, member states also agreed to improve manufacturing capacities across the alliance and continue investing in joint projects with Ukraine.
-
Why the US military needs an “innovation intervention”
Several issues in the Pentagon’s structure and the defence industrial base have been hampering the country's efforts to produce cutting-edge solutions.